NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Completion of Enrollment of its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression -January 22, 2024 at 06:49 am EST : vimarsana.com

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Completion of Enrollment of its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression -January 22, 2024 at 06:49 am EST

Exceeded originally target enrollment with n=74 Last patient, last visit expected in approximately six weeks; data to follow shortly thereafterPositive...

Related Keywords

Massachusetts , United States , France , French , Andrew Nierenberg , Jonathan Javitt , Nasdaq , Alvogen Pharmaceuticals , Prnewswire Nrx Pharmaceuticals Inc , Nrxp Nrx Pharmaceuticals , Us National Institutes Of Health , Nrx Pharmaceuticals Inc , Source Nrx Pharmaceuticals , Nrx Pharmaceuticals , Suicidal Treatment Resistant Bipolar , Breakthrough Therapy Designation , Chief Scientist , Principal Investigator , Harvard Massachusetts General , Clinical Global Impression Suicidality Scale , Breakthrough Therapy , New Drug Application , Fast Track Designation , Securities Litigation Reform Act , Markets ,